18 criteria for choosing GSK's Cervarix
This article was originally published in Scrip
Executive Summary
For those wondering how the department of health chose between GlaxoSmithKline's Cervarix and Sanofi Pasteur MSD's Gardasil for the UK's cervical cancer vaccine campaign (Scrip No 3373, p 1), health minister Dawn Primarolo has listed in a recent parliamentary answer the 18 criteria that were used. As well as the obvious clinical and cost reasons, the criteria include pallet configuration, the robustness of manufacturing contingency arrangements, the risk of wastage if subjected to temperatures above 8°C, and the closeness of delivery schedules to requirements.
You may also be interested in...
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.